This discussion breaks down the current state of artificial intelligence integration within the pharmaceutical sector. We examine why scaling AI solutions is a major hurdle for many organisations and how to overcome the gap between technical capability and actual deployment. This is essential viewing for anyone trying to navigate the complexities of adopting advanced technologies in a highly regulated environment.

If you are a vendor selling to pharma, the advice provided here is critical. We discuss why generic pitches fail and why presenting concrete AI business cases is the only way to secure buy-in from stakeholders. Instead of focusing on hype, learn how to demonstrate measurable ROI and operational efficiency to decision-makers who need to see real-world results before committing to new partnerships.

Subscribe for weekly B2B strategy breakdowns, and comment below on which industry sector you want us to analyse next.

Chapters

00:00 Introduction to AI's role in healthcare decision-making

02:28 Flora Eduard's background and industry transformation

06:40 The surprising lack of data use in pharma decision-making

08:11 Leadership principles Flora refuses to compromise

12:45 Cultural insights from working across countries

16:08 Biggest setbacks and lessons learned

22:39 Digital transformation vs. digitization

28:41 Current state of AI experimentation in pharma

31:52 Understanding agentic AI and its differences from traditional AI

34:45 The future of AI and how soon it will arrive

40:49 AI's potential to improve patient outcomes

45:33 Skills needed for future leaders in the AI era

01:10:10 The future of pharma in 2035

01:11:48 Rapid fire insights and predictions

Get vidIQ to grow your channel faster! 🚀https://vidiq.com/DrugDiaries Learn how to approach AI in pharma by focusing on proven business cases rather than theoretical potential. Discover what works today.